Special Encore: U.S. Pharmaceuticals - The Fu...

Our Head of U.S. Pharma and Biotech Terence Flynn discusses how the rapid pace of adoption of weight management treatments could have far-reaching implications across healthcare, consumer behavior and global markets.Read more insights from Morgan Stanley.----- Transcript -----Wel ...  Show more

Our Global Head of Fixed Income Research Andrew Sheets breaks down how Péter Magyar’s win in Hungary’s election could smooth relations with the EU and lower the risk premium in the country’s assets.Read more insights from Morgan Stanley.----- Transcript -----Welcome to Thoughts o ...  Show more

with Andrew Lo (@AndrewWLo) and Jorge Conde (@JorgeCondeBio)

The advent of new gene and cell therapies are beginning to approach that holy grail of medicine—that of a possible cure. But they are also more expensive than any medicines ever sold before. In this episode, M ...

Mapping the human genome led to big advances in diagnosing rare disease. But diagnosis is only the first step in dealing with an illness. So what do you do if your child is found to have a condition that has no treatment? We hear from Michelle Teng, a mother who co-founded a biot ...  Show more

with Vas Narasimhan (@vasnarasimhan), Jorge Conde (@jorgecondebio), Vijay Pande (@vijaypande), and Sonal Chokshi (@smc90)

On average, only 1 out of 20 medicines works when we actually bring them into the human body, and these rates of success haven't moved much in the ph ...

Speaking with the CEO and founder of a pharmaceutical company was an incredible experience. William Stilley knows the science inside and out. And, he is able to explain it clearly, in understandable terms. What makes Adial different from many of the well-known drug companies is t ...  Show more